Restrictive vs Liberal Transfusion Strategy After Myocardial Infarction
JAMA Network Open · 27 Jul 2026
† Impact is the editorial-priority score. All scores are out of 100. Clinical is a stored clinical-importance score from the earlier method; it has not been recalculated.
Why it matters
Anemic MI patients are common in both cardiology and perioperative orthopaedic settings, and this reanalysis illustrates how a 'negative' P=.07 trial can be reframed as supportive evidence using Bayesian statistics, a distinction trainees should recognise when reading transfusion literature.
The evidence
This is a post hoc Bayesian reanalysis of the MINT trial, which randomised 3504 patients with myocardial infarction and anaemia to a restrictive (transfuse below Hgb 7-8 g/dL) versus liberal (keep Hgb above 10 g/dL) transfusion strategy. The original frequentist result for 30-day death or MI was borderline (crude risk ratio 1.16, 95% CI 1.00-1.35, with 16.9% events in the restrictive arm vs 14.5% in the liberal arm), so the authors reanalyzed the same data using Bayesian methods and found an 89.1% to 98.8% posterior probability that the liberal strategy reduced death or MI, at the cost of a modestly higher (60.6%-80.0% probability) risk of heart failure.
30-day death or myocardial infarction: Risk ratio 1.16 (95% CI 1 to 1.35; units not reported). The interval includes no difference. This does not establish equivalence or rule out an important effect.
Why this rigour score?
Multicentre RCTDesign starting point: 63.4
Raised the score
- Prospectively registered+5.1
- Intention-to-treat analysis+3.4
Lowered the score
- Only 1 months of follow-up−6.8
- Unblinded outcome assessment−3.4
Score capped at 40. The conclusions are not supported by the reported results.
Methods at a glance
Recorded assessment- Outcome assessors blindedNot met
- Allocation concealedNot reported
- Random sequence generatedNot reported
- Intention-to-treat analysisMet
- Adequate statistical powerNot applicable
- Prospective registrationMet
Not reported does not mean not done. Checks have different weights; this is not a count of boxes ticked.
See the full score breakdown
- Study design starting point
- 63.4
- Compared against an accepted alternative
- +1.7
- Unblinded outcome assessment
- −3.4
- Intention-to-treat analysis
- +3.4
- Only 1 months of follow-up
- −6.8
- 0% loss to follow-up
- +1.7
- Prospectively registered
- +5.1
- No correction for multiple comparisons
- −3.4
- Methodological cap
- −21.7
- Final rigour score rounded
- 40 / 100
Study design sets the starting point and a ceiling of 100. Recorded methods then adjust the score. Points are shown to one decimal place; the final score uses unrounded values.
Checklist from the stored appraisal. “Not met” describes the recorded criterion; it does not always produce a deduction. This overview supports reading the full study.
For journal club
1.For an anemic patient with a recent MI who needs orthopaedic surgery, should the perioperative transfusion threshold be raised toward 10 g/dL despite the small added heart failure risk this analysis suggests?
2.How should surgeons weigh a borderline (P=.07) frequentist trial result against a Bayesian reanalysis suggesting high probability of benefit when deciding transfusion thresholds for their own anemic surgical patients?
Original publication title
Restrictive vs Liberal Transfusion Strategy After Myocardial Infarction